Core Viewpoint - Kahn Swick & Foti, LLC has initiated an investigation into Lantheus Holdings, Inc. following a significant decline in revenue from its primary product, Pylarify, which contradicts the company's previous optimistic growth outlook [1] Company Performance - In August 2025, Lantheus Holdings reported an 8% year-over-year decline in revenue from Pylarify [1] - The company has also made cuts to its full-year revenue projections, indicating potential challenges ahead [1]

Core Viewpoint - Lantheus Holdings, Inc. (NASDAQ:LNTH) is considered a promising investment in the healthcare sector, with a significant portion of analysts recommending a 'Buy' rating and a median price target indicating potential upside [1][2]. Analyst Ratings - Approximately 80% of analysts covering Lantheus Holdings have assigned a 'Buy' or equivalent rating, with a median price target of $75, suggesting an upside potential of 18.48% from the current price [1]. - Jefferies analyst Matthew Taylor maintains a 'Buy' rating with a price target of $105, indicating a potential upside of 66% [2]. - Leerink Partners has reduced its price target from $97 to $90 while keeping an 'Overweight' rating, citing concerns over pricing pressures and competitive dynamics affecting the Pylarify franchise [3]. Financial Performance - In the third quarter results announced on November 6, Lantheus reported mixed financial outcomes, with revenue exceeding consensus estimates by approximately 5%, while diluted EPS fell 2% short of expectations [4]. - The decline in Pylarify revenues was attributed to "340B best price-driven price compression and competitive pressures from Ga-68 PSMA PET agents at large accounts" [4]. Company Overview - Lantheus Holdings, Inc. is a Massachusetts-based company that specializes in diagnostic and therapeutic products for various diseases, with a history dating back to 1956 [4].

Core Insights - The healthcare sector is highlighted as a promising investment opportunity heading into 2026, with many stocks remaining undervalued despite the sector's resilience and growth since the pandemic [1][2][3]. Group 1: Market Outlook - JPMorgan has upgraded the healthcare sector to a preferred investment area, citing easing policy overhang, clarity in earnings, and increased M&A activity as key factors for this positive outlook [2][3]. - The strategists believe that the healthcare sector is showing signs of stabilization and renewed momentum, positioning it favorably for 2026 and beyond [3]. Group 2: Stock Selection Methodology - The list of recommended cheap healthcare stocks is based on companies with a market capitalization exceeding $2 billion, covered by three or more analysts, and showing an upside potential of over 10% with a forward P/E ratio between 8 and 15 [5]. - The top 12 companies were ranked based on their highest upside potential, with additional data on hedge fund holdings included [5][6]. Group 3: Company Highlights - **ICON Public Limited Company (NASDAQ:ICLR)**: - Upside potential of 14.87% as of December 5, 2025, with a share price of $185.87 [8]. - Maintained a 'Market Perform' rating with a price target of $175, indicating ongoing discussions about executive changes and revenue trends [8][10]. - Analysts generally rate it as a 'Buy' with a median price target of $213.50, suggesting nearly 15% upside [11]. - **Lantheus Holdings, Inc. (NASDAQ:LNTH)**: - Upside potential of 18.48% as of December 5, 2025, with a share price of $63.30 [12]. - Almost 80% of analysts rate it as a 'Buy', with a median price target of $75, indicating strong growth potential [12]. - Recent financial performance showed mixed results, with revenue exceeding estimates but diluted EPS falling short, attributed to pricing pressures and competitive dynamics [15].

Core Viewpoint - Grabar Law Office is investigating claims on behalf of shareholders of Lantheus Holdings, Inc. regarding potential breaches of fiduciary duties by certain officers and directors [1]. Group 1: Investigation Details - The investigation focuses on whether Lantheus Holdings' officers and directors made false statements or concealed information about the company's revenue outlook and growth potential [3]. - Allegations include that the company misrepresented its understanding of market dynamics, particularly regarding the sales growth potential and pricing of its product Pylarify [3]. Group 2: Shareholder Actions - Shareholders who purchased Lantheus Holdings shares prior to November 6, 2024, and still hold them can seek corporate reforms and the return of funds to the company at no cost [2][4]. - Interested shareholders are encouraged to contact Grabar Law Office for more information on the investigation and potential actions [2][4].

Core Points - The Gross Law Firm has issued a notice to shareholders of Lantheus Holdings, Inc. regarding a class action lawsuit related to misleading statements about the company's revenue outlook and market conditions [1][3] - The class period for the lawsuit is from February 26, 2025, to August 5, 2025, during which shareholders are encouraged to register for potential recovery [3][4] - Allegations include that Lantheus misrepresented its understanding of the competitive dynamics and pricing of its product Pylarify, leading to inflated stock prices [3] Summary by Sections Class Action Details - Shareholders who purchased shares of Lantheus during the specified class period are invited to contact the Gross Law Firm for possible lead plaintiff appointment [1][4] - The deadline for shareholders to register for the class action is November 10, 2025 [4] Allegations Against Lantheus - The complaint alleges that Lantheus made false statements regarding its revenue projections and growth potential, while downplaying risks from competition and market fluctuations [3] - The company's optimistic reports on Pylarify's sales growth were found to be misleading, as they did not accurately reflect market conditions [3] Firm's Commitment - The Gross Law Firm aims to protect investors' rights and ensure companies engage in responsible business practices [5] - The firm seeks recovery for investors who suffered losses due to misleading statements that artificially inflated stock prices [5]

Nov 10, 2025 11:20 AM Eastern Standard Time LNTH FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Announces that Lantheus Investors Have Opportunity to Lead Class Action Lawsuit Share Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Lantheus To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Lantheus between November 6, 2024 and August 6, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi ...

Core Viewpoint - Rosen Law Firm is urging investors of Lantheus Holdings, Inc. to secure legal counsel before the November 10, 2025 deadline for a securities class action lawsuit related to the company's performance during the specified class period [1][3]. Group 1: Class Action Details - Investors who purchased Lantheus securities between February 26, 2025, and August 5, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must act by the November 10, 2025 deadline to serve as lead plaintiff [3][5]. - The lawsuit alleges that Lantheus provided misleading statements about its product Pylarify, failing to disclose critical information regarding its competitive position and pricing strategy, which ultimately harmed investors when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering hundreds of millions for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, achieving significant recoveries, including over $438 million in 2019 alone [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Lantheus Holdings, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on November 10, 2025 [1]. Group 1: Class Action Details - Investors who purchased Lantheus securities between February 26, 2025, and August 5, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 10, 2025 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that Lantheus provided misleading statements regarding the competitive position of its product, Pylarify, while failing to disclose critical information about pricing and market dynamics [5]. - It is claimed that Lantheus's early 2025 price increase, despite previous price erosion, created opportunities for competitive pricing that jeopardized Pylarify's market position and revenue potential [5].

Core Points - Rosen Law Firm is reminding investors of Lantheus Holdings, Inc. about the November 10, 2025 deadline to join a securities class action lawsuit related to the company's stock performance during the Class Period from February 26, 2025, to August 5, 2025 [1][2]. Group 1: Class Action Details - Investors who purchased Lantheus securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 10, 2025 [3]. - The lawsuit alleges that Lantheus provided misleading statements about its product Pylarify, failing to disclose critical information regarding its competitive position and pricing strategy [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - Rosen Law Firm has a history of successful settlements in securities class actions, including a notable settlement against a Chinese company and has recovered hundreds of millions for investors [4]. Group 3: Case Background - The lawsuit claims that Lantheus made overwhelmingly positive statements while concealing material adverse facts about Pylarify's market position, which led to investor damages when the truth was revealed [5].

Core Viewpoint - Lantheus Holdings, Inc. is facing a securities class action lawsuit due to allegations of providing misleading statements regarding its product Pylarify, with a lead plaintiff deadline set for November 10, 2025 [1][5]. Group 1: Class Action Details - The class action pertains to investors who purchased Lantheus securities between February 26, 2025, and August 5, 2025, and may be entitled to compensation without upfront fees [2][5]. - A lawsuit has already been filed, and interested parties must act by the November 10, 2025 deadline to serve as lead plaintiff [3][5]. Group 2: Allegations Against Lantheus - The lawsuit claims that Lantheus made overly positive statements while concealing material adverse facts about Pylarify's competitive position [5]. - It is alleged that Lantheus failed to adequately assess pricing dynamics and that a price increase in early 2025, despite previous price erosion, risked Pylarify's market position and revenue potential [5]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel, highlighting its track record in securities class actions and significant settlements [4]. - The firm has recovered hundreds of millions for investors, including over $438 million in 2019, and has been consistently ranked among the top firms in this area since 2013 [4].